Tevogen Bio Holdings Inc. TVGN 深 沪

Tevogen Creates Healthcare Services Initiative Led By VP Of Strategic Initiatives William Keane On Interim Basis

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the formation of its healthcare services initiative, a strategic business area intended to support the Company's evolution into a broader,

06-10 03:32

Tevogen Announces Formation of a Healthcare Services Initiative

Tevogen announced the formation of its healthcare services initiative, led by William Keane as interim head, to evaluate potential acquisitions of a Management Services Organization (MSO) and a Contract Research Organization (CRO). These acquisitions aim to generate approximately $100 million in annual revenue and support the company's mission to improve healthcare affordability and access. The initiative complements Tevogen's existing biotechnol...

06-09 19:30

Tevogen Bio shares are trading higher after the company announced continued progress across its strategic acquisition initiatives.

Tevogen Bio shares are trading higher after the company announced continued pro...

05-29 02:24

Tevogen Bio Holdings shares are trading higher after the company announced it signed a non-binding Letter of Intent to evaluate a potential transaction with a Management Services Organization.

Tevogen Bio Holdings shares are trading higher after the company announced it s...

05-22 00:39

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

Tevogen Bio Holdings Inc. has signed a non-binding Letter of Intent to evaluate a potential acquisition of a Management Services Organization (MSO). This transaction could enhance the company's healthcare infrastructure and support its growth into a revenue-generating enterprise combining Tevogen Bio (biotechnology), Tevogen.AI (technology), and a potential healthcare services arm. CEO Ryan Saadi, MD, MPH, expects the deal, along with other initi...

05-21 16:15

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen CEO Dr. Ryan Saadi updates shareholders on the company's progress since its 2024 public listing, highlighting a 51% decline in operational losses from 2024 to 2025 and a 48% improvement in Q1 2026. The company advanced initiatives like Tevogen.AI and expanded its cell therapy pipeline while maintaining disciplined capital allocation. Potential revenue-generating acquisitions are under evaluation, and long-term incentives are being aligned...

05-18 16:15

Tevogen Bio Holdings Q1 EPS $(1.61) Beats $(2.50) Estimate

Tevogen Bio Holdings (NASDAQ:TVGN) reported quarterly losses of $(1.61) per share which beat the analyst consensus estimate of $(2.50) by 35.6 percent. This is a 50.46 percent increase over losses of $(3.25) per share

05-16 06:57

Tevogen Enters $3M Private Placement PIPE Financing At $8.00/Prefunded Warrant, Issuing 375K Warrants Each Exercisable For The Purchase Of 1 Share Of The Company's Common Stock

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a securities purchase agreement for a private investment in public equity (the "PIPE") financing with existing

05-12 23:48

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) announced a $3 million private investment in public equity (PIPE) financing with existing investor The Patel Family, LLP. The proceeds will support operations, strategic growth, and general corporate purposes. Tevogen will issue 375,000 prefunded warrants priced at $8.00 each, a 14% premium to the May 11 closing price. The financing is expected to close on May 13. Tevogen plans to use the funds alongside a...

05-12 15:45

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

04-27 15:50